Published in J Reticuloendothel Soc on October 01, 1978
Activation of Fc receptor-bearing lymphocytes by immune complexes. II. Killer lymphocytes mediate Fc ligand-induced lymphokine production. J Exp Med (1981) 0.79
Release of lymphotoxin by control and chemical carcinogen-treated lymphocyte cultures derived from black healthy subjects and cancer patients. J Natl Med Assoc (1982) 0.75
Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell (1990) 5.73
Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction. J Immunol (1968) 4.66
Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med (1989) 2.33
Lymphocyte cytotoxicity in vitro: activation and release of a cytotoxic factor. Nature (1968) 2.24
Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol (1987) 2.08
Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Natl Acad Sci U S A (1968) 1.95
Lymphocyte in vitro cytotoxicity: specific release of lymphotoxin-like materials from tuberculin-sensitive lymphoid cells. Nature (1969) 1.94
NKR-P1, a signal transduction molecule on natural killer cells. Science (1990) 1.94
Chromatographic alterations in transfer RNA's accompanying speciation, differentiation and tumor formation. J Mol Biol (1968) 1.88
Efficient, inefficient, and abortive infection of different mammalian cells by small RNA viruses. Virology (1967) 1.88
Homograft target cells: contact destruction in vitro by immune macrophages. Science (1966) 1.77
The in vitro induction and release of a cell toxin by immune C57B1-6 mouse peritoneal macrophages. Cell Immunol (1972) 1.73
Lymphocyte in vitro cytotoxicity: mechanism of lymphotoxin-induced target cell destruction. J Immunol (1969) 1.60
Lymphocyte in vitro cytotoxicity: correlation of derepression with release of lymphotoxin from human lymphocytes. J Immunol (1969) 1.53
Characterization of the cytolytic reaction mechanism of the human natural killer (NK) lymphocyte: resolution into binding, programming, and killer cell-independent steps. J Immunol (1982) 1.51
The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes. J Immunol (1988) 1.47
Production of lymphotoxin and migration inhibitory factor by established human lymphocytic cell lines. J Immunol (1970) 1.43
The human LT system. I. Physical-chemical heterogeneity of LT molecules released by mitogen activated human lymphocytes in vitro. Cell Immunol (1978) 1.40
Lymphocyte in vitro cytotoxicity: lymphotoxins of several mammalian species. Nature (1968) 1.39
Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A (1990) 1.34
NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and a rise in intracellular calcium. J Immunol (1991) 1.31
Relationship of cloning inhibition factor, "lymphotoxin" factor, and proliferation inhibition factor release in vitro by mitogen-activated human lymphoctes. J Immunol (1975) 1.24
Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation (1991) 1.22
Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol (1989) 1.19
Isolation and initial characterization of tumoricidal monokine(s) from the human monocytic leukemia cell line THP-1. J Natl Cancer Inst (1985) 1.16
Similarities and differences among specific tRNA's in mammalian tissues. Proc Natl Acad Sci U S A (1967) 1.15
An improved in vitro assay for lymphotoxin. Cell Immunol (1972) 1.14
Hypoxia induces a human macrophage cell line to release tumor necrosis factor-alpha and its soluble receptors in vitro. J Surg Res (1993) 1.14
Lymphocyte in vitro cytotoxicity: characterization of mouse lymphotoxin. Cell Immunol (1970) 1.12
A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res (1988) 1.10
In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J Exp Med (1990) 1.10
Phorbol myristate acetate induction of lymphotoxins from continuous human B lymphoid cell lines in vitro. J Biol Response Mod (1984) 1.10
Studies on in vitro models of cellular immunity: the role of T and B cells in the secretion of lymphotoxin. Cell Immunol (1973) 1.09
Cell-mediated immunity in vitro: a highly sensitive assay for human lymphotoxin. J Immunol (1974) 1.07
The human LT system. XII. Purification and functional studies of LT and "TNF-like" LT forms from a continuous human T cell line. J Immunol (1986) 1.05
The regulation of TNF receptor mRNA synthesis, membrane expression, and release by PMA- and LPS-stimulated human monocytic THP-1 cells in vitro. Cell Immunol (1991) 1.05
The human LT system. XI. Identification of LT and "TNF-like" forms from stimulated natural killers, specific and nonspecific cytotoxic human T cells in vitro. J Immunol (1986) 1.01
Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res (1989) 1.00
Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw (1993) 1.00
Purified native and recombinant human alpha lymphotoxin [tumor necrosis factor (TNF)-beta] induces inflammatory reactions in normal skin. J Clin Immunol (1987) 0.98
Binding of human lymphotoxin to target-cell membranes and its relation to cell-mediated cytodestruction. Proc Natl Acad Sci U S A (1973) 0.98
Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J Exp Med (1988) 0.98
Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats. J Immunother (1991) (1991) 0.97
Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol (1996) 0.95
In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. Cell Immunol (1988) 0.94
Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro. Immunobiology (1999) 0.93
Flow-cytometric evaluation of lymphocyte subpopulations in synchronously developing Schistosoma mansoni egg and Sephadex bead pulmonary granulomas. Am J Pathol (1988) 0.93
Expression of a laminin-like substance on the surface of murine natural killer (NK) lymphocytes and its role in NK recognition of tumor target cells. J Immunol (1985) 0.93
Regulation of growth of human diploid fibroblasts by factors elaborated by activated lymphoid cells. J Cell Physiol (1982) 0.93
Mechanisms of lymphocyte-induced cell and tissue destruction in vitro. Am J Pathol (1970) 0.92
Lymphocyte effector molecules and cell-mediated immune reactions. Contemp Top Mol Immunol (1975) 0.91
Recombinant human alpha lymphotoxin (tumor necrosis factor-beta) induces peripheral neutrophilia and lymphopenia in the rat. Am J Pathol (1987) 0.91
Trauma causes sustained elevation of soluble tumor necrosis factor receptors. J Am Coll Surg (1994) 0.89
The presence of antibodies to lymphotoxin and tumor necrosis factor in normal serum. Arthritis Rheum (1989) 0.88
Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res (1995) 0.88
Lymphokines--the mediators of cellular immunity. Ser Haematol (1972) 0.88
Mechanisms of lymphocyte-mediated cytotoxicity. I. The effects of anti-human lymphotoxin antisera on the cytolysis of allogeneic B cell lines by MLC-sensitized human lymphocytes in vitro. J Immunol (1981) 0.87
The role of lymphotoxin in target cell destruction by mitogen-activated human lymphocytes. I. The correlation of target cell sensitivity to lymphotoxin and the intact lymphocyte. Cell Immunol (1975) 0.87
Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Cancer Res (1988) 0.87
Lymphocyte in vitro cytotoxicity: mechanism of human lymphotoxin-induced target cell destruction. Cell Immunol (1973) 0.87
Role of 55- and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro. J Immunol (1993) 0.87
Studies on the mechanism of the human natural killer cell lethal hit: analysis of the mechanism of protease inhibition of the lethal hit. J Immunol (1983) 0.87
In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell Immunol (1990) 0.87
Mechanism of release of soluble forms of tumor necrosis factor/lymphotoxin receptors by phorbol myristate acetate-stimulated human THP-1 cells in vitro. J Immunol (1993) 0.86
In vitro lymphocyte cytotoxicity. I. Evidence of multiple cytotoxic molecules secreted by mitogen activated human lymphoid cells in vitro. Cell Immunol (1976) 0.86
Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol Biol Phys (1997) 0.86
Lymphotoxins: a multicomponent system of cell-lytic lymphocyte-released effector molecules. Lymphokine Res (1982) 0.85
Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients. Lymphokine Res (1990) 0.85
Production of lymphotoxin by isolated human tonsillar B lymphocytes and B lymphocyte cell lines. J Clin Invest (1989) 0.85
Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Cancer Res (1988) 0.85
Prostaglandin-E2 regulation of tumor necrosis factor receptor release in human monocytic THP-1 cells. Cell Immunol (1996) 0.84
Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Int J Cancer (1996) 0.84
Lymphotoxin detected in the blister fluid of bullous pemphigoid patients. J Clin Immunol (1984) 0.83
Reduced natural killer cell activity in patients with systemic sclerosis. Correlation with clinical disease type. Arthritis Rheum (1988) 0.83
In situ localization of 3.2.3+ natural killer cells in tissues from normal and tumor-bearing rats. Cancer Res (1991) 0.83
Trauma causes early release of soluble receptors for tumor necrosis factor. J Trauma (1993) 0.83
Relationship of CIF, LT, and PIF released in vitro by activated human lymphocytes. II. A further functional comparison of LT and PIF activities on HeLa and L-929 target cells. J Immunol (1976) 0.83
The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. J Exp Med (1990) 0.83
Studies of membrane-associated and soluble (secreted) lymphotoxin in human lymphokine-activated T-killer cells in vitro. Lymphokine Cytokine Res (1992) 0.82
Relationship between cutaneous delayed hypersensitivity and cell-mediated immunity in vitro responses assessed by diphtheria and tetanus toxoids. J Allergy Clin Immunol (1977) 0.82
Immunotherapy with transfer factor in disseminated coccidioidal osteomyelitis and arthritis. West J Med (1974) 0.82
Mechanism of human lymphotoxin and tumor necrosis factor induced destruction of cells in vitro: phospholipase activation and deacylation of specific-membrane phospholipids. J Cell Physiol (1990) 0.82
Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro. Biochem Biophys Res Commun (1996) 0.82
Antibodies against human lymphokines: I. Methods for induction of antibodies capable of neutralizing stable (alpha) and unstable (beta) lymphotoxins released in vitro by activated human lymphocytes. J Immunol Methods (1977) 0.82
Human lymphotoxin: purification and some properties. Proc Natl Acad Sci U S A (1973) 0.82
The human LT system. V. A comparison of the relative lytic effectiveness of various MW human LT classes on 51Cr-labeled allogeneic target cells in vitro: enhanced lysis by LT complexes associated with Ig-like receptor(s). Cell Immunol (1979) 0.81
Effects of splenectomy on the development of tumor-specific immunity. J Surg Res (1990) 0.81
Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor. J Immunol (1999) 0.81
NKR-P1+ cells in the rat uterus: granulated metrial gland cells are of the natural killer cell lineage. Biol Reprod (1994) 0.81